entertainment -WSS

entertainment

author：knowledge 2025-09-02 05:50:25 - browse：679

a stethoscope and money – hospitals and health insurance coverage from STAT — Bright Health is officially leaving the health insurance market. The company has agreed to sell its Medicare Advantage plans to Molina Healthcare. Adobe

Bright Health Group has agreed to sell its Medicare Advantage plans to its publicly traded peer Molina Healthcare.

Regulators must approve the deal. But the pending sale of its Medicare Advantage business means the financially distressed Bright has exited the health insurance market that the company was founded on. It will solely operate roughly 70 physician clinics located in California, Texas, and Florida.

Molina agreed to pay $600 million for Bright’s 125,000 California Medicare Advantage enrollees, which equates to about $4,800 for each person. The federal government paid insurance companies almost $12,000, on average, for each MA enrollee in 2022. Molina said in a news release that Bright’s current book of business generates $1.8 billion of revenue, or more than $14,000 for each member.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Physician executives need more than on

hotspot

WSS

Lawsuit highlights wrinkle for disputes over surprise medical bills

Nobel honors Karikó and Weissman's enduring partnership

CDC picks Alphabet's Verily for wasterwater surveillance contract

FDA rejects Alnylam's heart disease treatment over insufficient data

FDA rejects Alnylam's heart disease treatment over insufficient data

CRISPR base editing slashes cholesterol levels in monkeys

hotspot

entertainment

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

FDA rejects Alnylam's heart disease treatment over insufficient data

Hepatitis C has a cure — but many Americans still lack access to it

Physician executives need more than on

In age of alternative facts, a scholarly course on calling out crap

What to expect at HLTH 2023, the health care industry conference

Drug repurposing or repositioning? The language matters

FDA panel signals lack of confidence in Amgen cancer drug data

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

hotspot

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Health insurers' Q3 question: how much care are people getting?

Phenylephrine and the overlooked value of the placebo effect

The future of health care in the House

IVG is promising — but it won’t replace IVF quite yet

Why age limits for politicians are a terrible idea

focus

focus

hotspot

explore